Cambridge Healthtech Institute’s 4th Annual

Personalized Cancer Vaccines

Advancing Personalized and Combination Immunotherapy

August 8-9, 2019



Recent developments in personalized cancer vaccines are enabling the next generation of rational cancer immunotherapy. Cancer vaccines may now be combined with other immunotherapies, dendritic cells used for personalized immunotherapy, and neoantigens on the surface of cancer cells targeted, matching vaccine components to each patient. mRNA- and DNA-based vaccines present an additional opportunity for cancer therapeutics. Cambridge Healthtech Institute’s Fourth Annual Personalized Cancer Vaccines conference will cover applications in several types of cancer and progress in the understanding of the immune system that has significantly advanced the potential of cancer vaccines.

Final Agenda

THURSDAY, AUGUST 8

7:45 am Registration Open and Morning Coffee


8:30 PLENARY KEYNOTE SESSION

PANEL DISCUSSION: Partnering and Licensing in Immuno-Oncology

Big pharma and biotech are under pressure to compete in the booming Immuno-Oncology market and to capitalize on new technologies and innovations to bring next-generation immunotherapies to the patients. This insider panel will share what they look for in a partner or investment, and discuss opportunities for collaboration or in-licensing of novel immunotherapies, IO targets or biomarkers, and potential combination therapies.

Moderator

Jeroen H. Blokhuis, PhD

Director, Business Development, Partnerships, Parker Institute for Cancer Immunotherapy

 

 

 

 

Panelists

Michael Woo, MBA

Head, Search & Evaluation, Immuno-Oncology, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.

 

 

 

 

Kathryn McCabe, PhD

Senior Director, Business Development, Emerging Technology and Innovation, Eli Lilly and Company

 

 

 

 

Scott M. DeWire, PhD

Global Head, Business Development and Licensing, Cancer Immunology, Boehringer Ingelheim Pharmaceuticals, Inc.

 

 

 

 

Philip Arlen, MD

President & CEO, Precision Biologics

 

 

 

 

Stephen Doberstein, PhD

Senior Vice President, R&D and Chief Research and Development Officer, Nektar Therapeutics

 

 

 

 

9:30 Coffee Break in the Exhibit Hall. Last chance for poster viewing.

PERSONALIZED VACCINES

10:10 Chairperson’s Opening Remarks

Stephen Doberstein, PhD, Senior Vice President, R&D and Chief Research and Development Officer, Nektar Therapeutics

10:15 Th17 T Helper Cell Vaccines for Treatment and Prevention of Cancer

Knutson_KeithKeith Knutson, PhD, Professor, Immunology, Director, Immunology & Immunotherapy Program, Mayo Clinic

In ovarian cancer (OC), IL-17-producing T cells (Th17s) predict improved survival. We developed a method whereby autologous dendritic cells can be programmed to induce Th17 responses to OC antigens. In both preclinical and clinical vaccination studies, results demonstrate that durable tumor-antigen-specific Th17s can be generated. Vaccination led to greatly improved progression free survival in murine models and in humans. Additional studies demonstrate strong synergistic efficacy when used with immune checkpoint blockade.

10:45 Personalizing Cancer Vaccines by Pairing Off-the-Shelf Strategies with Optimal Patient Selection

Heery_ChristopherChristopher R. Heery, MD, CMO, Bavarian Nordic

A personalized approach to therapeutic cancer vaccination may be necessary to drive optimal cancer-specific T cell responses. However, patient-specific vaccination strategies face regulatory, quality control, and manufacturing hurdles. An alternative approach for consideration is a panel of therapeutic vaccine targets known to be expressed in a particular indication with epitopes relevant for a variety of HLA subtypes. Then, a patient can be matched to an optimal vaccine based on HLA type, tumor expression, and likelihood of T cell activation and expansion based on novel and available techniques.

11:15 Use of Enveloped Virus-Like Particles (eVLPs) in Immuno-Oncology

Anderson_DavidDavid E. Anderson, PhD, CSO, VBI Vaccines

The talk will summarize the strong potency observed thus far in a Phase I/IIa trial with VBI-1901, an eVLP-based vaccine against glioblastoma. New preclinical data will highlight the ability to express a variety of immunomodulatory molecules on the surface of eVLPs to further enhance potency and shape anti-tumor immunity.

11:45 Sponsored Presentation (Opportunity Available)

12:15 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:45 Session Break

DENDRITIC CELL VACCINES

1:40 Chairperson’s Remarks

Jay A. Berzofsky, MD, PhD, Chief, Vaccine Branch, Center for Cancer Research, National Cancer Institute


1:45 KEYNOTE PRESENTATION: Autologous Dendritic Cell Vaccines for Prostate and HER2-Expressing Cancers

Jay A. Berzofsky, MD, PhD, Chief, Vaccine Branch, Center for Cancer Research, National Cancer Institute

We have developed several cancer vaccines based on use of autologous dendritic cells (DCs) presenting the vaccine antigen. One vaccine targets prostate cancer with peptide epitopes from the prostate cancer antigen TARP, modified by epitope enhancement to improve immunogenicity. The second targets tumors expressing HER2, including breast, colon, ovarian, gastric, prostate, lung, and others, using an adenovirus expressing part of HER2 to transduce the DCs. The strategy is designed to bypass poor DC maturation in cancer patients by maturing the DCs ex vivo, and in the case of the Ad-HER2, to avoid neutralization by anti-adenovirus antibodies. Factors that promote DC efficacy have also been analyzed. Both vaccines show promise in early clinical trials.

2:15 Personal Dendritic Cell Anti-Cancer Vaccines: Autologous Dendritic Cells Loaded with Tumor Antigens from Autologous Tumor Initiating Cells

Dillman_RobertRobert O. Dillman, MD, CMO, AIVITA Biomedical

We are manufacturing patient-specific anti-cancer vaccines (DC-ATA) consisting of autologous dendritic cells (DC) loaded with autologous tumor antigens (ATA) derived from short term-cell cultures of tumor-initiating cells. Clinical trials with first-generation DC-ATA demonstrated minimal toxicity and encouraging overall survival results in patients with metastatic melanoma and metastatic renal cell cancer. Trials are ongoing in newly-diagnosed advanced ovarian cancer, newly-diagnosed glioblastoma. and in combination with anti-PD-1 in metastatic melanoma.

2:45 Sponsored Presentation (Opportunity Available)

3:15 Refreshment Break

NEOANTIGEN SELECTION AND TARGETING

3:45 Identifying and Characterizing Neoantigens for Optimized Immunotherapies

Carroll_PamelaPamela Carroll, PhD, Senior Vice President, Immuno-Oncology, Genocea Biosciences

Genocea’s ATLASTM platform is a powerful tool that screens all candidate neoantigens for pre-existing patient-specific CD4+ or CD8+ stimulatory and inhibitory responses in an HLA agnostic assessment. Excluding inhibitory peptides that may suppress tumor immunity, accelerate tumor progression and mediate patient response to immune checkpoint blockade therapies could enable best-in-class immunotherapies. Genocea is applying ATLAS in its two lead programs: GEN-009, a neoantigen vaccine currently being evaluated in Phase 1/2a clinical trials, and GEN-011, a personalized non-engineered T cell therapy program that targets multiple neoantigens.

4:15 KEYNOTE PRESENTATION: Functional Identification and Therapeutic Targeting of Cancer Neoantigens

Stephen P. Schoenberger, PhD, Co-Director, San Diego Center for Precision Immunotherapy; Professor, La Jolla Institute for Allergy and Immunology

This presentation will describe a novel approach developed to identify the subset of expressed cancer mutations that can be recognized by a patient’s own immune system and which can form the basis for personalized immunotherapy by either vaccination or adoptive cellular therapy.

4:45 ASPH, a Focal Point for Broad Impact in Immuno-Oncology

Csiki_IldikoIldiko Csiki, MD, PhD, CMO, Sensei Biotherapeutics

Sensei Bio is pioneering therapeutic targeting of a novel and untapped tumor-specific antigen (TSA) called ASPH, a TSA with high prevalence in 20+ cancer types, both solid tumors and hematological malignancies; significant role in driving cancer cell proliferation and evading cancer detection by the immune system; over-expressed at 70% + prevalence in cancer; developing cell therapies and cancer vaccines along with companion diagnostic for patient selection. Sensei Bio also has a proprietary differentiated technology called SPIRIT platform which identifies immunodominant epitopes, activating T-and B-cells. By engineering antigen expression in an immunogenically optimized presentation, therapeutic candidates activate 3 arms of the immune system and induce cellular immunity associated with tumor growth inhibition.

5:15 Close of Day

FRIDAY, AUGUST 9

8:30 am Breakout Discussion Groups with Continental Breakfast

PERSONALIZED VACCINES FOR CANCER IMMUNOTHERAPY

9:30 Chairperson’s Remarks

Nathaniel Wang, PhD, Head of R&D, Synthetic Genomics, Inc.

9:35 Immunogenic Intensification – An Emerging Strategy to Enhance Cancer Immunotherapy

Bilusic_MarijoMarijo Bilusic, MD, PhD, Associate Research Physician, Program Director, NIH Hematology Oncology Fellowship, National Cancer Institute, National Institutes of Health

Preclinical studies have demonstrated that the combination of cancer vaccines and checkpoint inhibitors has synergistic effects. Cancer vaccines activate T cells, direct them to the tumor and increase PD-L1 expression within the tumor microenvironment. Vaccines should enhance immune response and, with concurrent blockade of inhibitory pathways, could also achieve optimal antitumor effects. Combinations of cancer vaccines and immune checkpoint inhibitors are currently being studied in clinical trials. Early results suggest that it is possible to combine immune agents with manageable side effects, while inducing anti-tumor activity in some patients. Combinations of cancer vaccine and immune checkpoint inhibitor may prove of significant added therapeutic benefit by immunogenic intensification.

10:05 Adenovirus Vectored Vaccines Targeting Multiple Neoantigens Synergize with Immune Checkpoint Inhibition to Eradicate Large Tumors

Scarselli_ElisaElisa Scarselli, CSO, Nouscom AG

Nouscom developed Gorilla Adenovirus vectored vaccines (GAds) with the capacity to encode multiple neoantigens. Experiments in murine cancer models demonstrated that GAd vaccination is very effective in early therapeutic settings, while it is not able to control tumor growth in the presence of high tumor burden. In this setting, the combination of GAd vaccine and anti-PD-1 broadens the repertoire of intra-tumor T cells and cures more animals than anti-PD-1 monotherapy.

10:35 Synthetic Self-Replicating RNA Platforms for Shared Neoantigen and Multidimensional Combination Therapeutics

Wang_NathanielNathaniel Wang, PhD, Head of R&D, Synthetic Genomics, Inc.

RNA as a vaccine and therapeutic modality has become a focus of significant interest. Synthetically Modified Alpha Replicon RNA Technologies (SMARRT) are capable of targeting neoantigens as a vaccine platform as well as co-expression of immunomodulatory molecules such as cytokines and antibodies for therapeutics. As a vaccine platform, SMARRT generates a high magnitude, polyfunctional Class I and Class II T cell response. Using this platform to target different classes of shared neoantigens in combination with immune modulators represents the next wave of multidimensional combination therapies.

11:05 Key Learnings from Bringing a Fully Personalized Cancer Neoantigen Vaccine into the Clinic

Fredriksen_AgneteAgnete Fredriksen, PhD, CSO, Vaccibody

Vaccibody has a unique platform technology able to potentiate DNA vaccines by attracting, activating and delivering antigens to antigen presenting cells. Positive clinical results have been proven with a therapeutic HPV vaccine in a phase I/IIa. The platform allows rapid and cost-effective manufacturing perfect to develop commercially viable patient-specific vaccines on demand. A Phase I testing Vaccibody neoantigen vaccine in advanced cancer patients receiving anti-PD/PD-L1 therapy was initiated in 2018.

11:35 am Close of Conference

Japan-Flag Korea-Flag China-Traditional-Flag China-Simplified-Flag


Connect With Us

MEETING SUGGESTIONS

For meeting questions or suggestions, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
juliab@healthtech.com

PARTNERING & SPONSORSHIP

For partnering and sponsorship info, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
+1 781.247.6286
reymael@healthtech.com

MEDIA & ASSOCIATION

For media and association partnerships, please contact:

Pete DeOlympio
Sr. Marketing Manager
Cambridge Healthtech Institute
+1 781.972.5415
peted@healthtech.com